Ion373    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
131Alexander disease1

131. Alexander disease    [ 1 clinical trial,   3 drugs,   (DrugBank: 1 drug),   0 drug target gene,   0 drug target pathway]
Searched query = "Alexander disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000976-40-GB
(EUCTR)
28/07/2020Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander DiseaseA Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease Alexander Disease
MedDRA version: 22.1;Level: PT;Classification code 10083059;Term: Alexander disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: ION373
Product Code: ION373
INN or Proposed INN: ION373
Other descriptive name: 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID
Ionis Pharmaceuticals, IncNULLNAFemale: yes
Male: yes
42Phase 1;Phase 2;Phase 3United States;Canada;Argentina;Australia;Israel;Netherlands;Japan;Italy;United Kingdom